CRISPR Therapeutics Aktie
| 46,55USD | 1,16USD | 2,56% |
WKN DE: A2AT0Z / ISIN: CH0334081137
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 96,02 |
| ARK Investment Management LLC | 11,44 |
| ARK Investment Management LLC | 9,24 |
| Capital Research & Management Co. (International Investors) | 7,64 |
| Capital Research & Management Co. (International Investors) | 7,00 |
| ARK Innovation ETF | 6,59 |
| Nikko Asset Management Americas, Inc. | 5,44 |
| T. Rowe Price Investment Management, Inc. | 4,59 |
| American Funds New Perspective Fund | 4,47 |
| Nikko Asset Management Americas, Inc. | 4,45 |
| Sumitomo Mitsui Trust Holdings, Inc. | 4,45 |
| Nikko AM Global Umbrella Fund - ARK Disruptive Innovation | 2,14 |
| State Street Corp. | 2,06 |
| NEA Management Co. LLC | 2,00 |
| NEA Management Co. | 2,00 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 188 | 304 | 410 | 473 | 458 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,02 | 0,95 | 0,00 | 1,93 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 466 | 963 | 1 716 | 2 418 | 1 853 |
| Summe Anlagevermögen | 392 | 992 | 1 726 | 2 624 | 2 120 |
| Summe Aktiva | 489 | 1 067 | 1 828 | 2 752 | 2 243 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 0 | 53 | 61 | 225 | 244 |
| Summe Fremdkapital | 97 | 127 | 164 | 352 | 368 |
| Summe Eigenkapital | 392 | 939 | 1 664 | 2 399 | 1 875 |
| Summe Passiva | 489 | 1 067 | 1 828 | 2 752 | 2 243 |
Adresse
| Baarerstrasse 14, 6300 Zug | |
| Telefon | +41 (41) 561-32-77 |
| Internet | http://www.crisprtx.com |
Management
|
Alex Harding
Head-Business Development & Senior Vice President |
|
Ali Behbahani
Independent Non-Executive Director |
|
Douglas A. Treco
Lead Independent Director |
|
Harold Edward Fleming
Independent Director |
|
James R. Kasinger
Secretary & General Counsel |
|
John T. Greene
Independent Director |
|
Jonathan Alexander Terrett
Head-Research |
|
Katherine A. High
Independent Director |
|
Maria Fardis
Independent Director |
|
Megan Wherry Menner
Head-Human Resources |
|
Phuong Khanh Morrow
Chief Medical Officer |
|
Raju Prasad
Chief Financial & Accounting Officer |
|
Samarth Kulkarni
Chairman & Chief Executive Officer |
|
Simeon J. George
Independent Non-Executive Director |
|
Stephen R. Kennedy
Head-Technical Operations |
|
Steven Caffé
Head-Regulatory Affairs |
|
Susan Kim
Investor Relations Contact |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
